Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile–based classification

Journal of the American Academy of Dermatology

Volumn 76, Issue 5, 2017, Pages 818-825.e3

  Ferris, Laura K ^a   Farberg, Aaron S ^b   Middlebrook, Brooke ^c   Johnson, Clare E ^c   Lassen, Natalie ^c   Oelschlager, Kristen M ^c   Maetzold, Derek J ^c   Cook, Robert W ^c   Rigel, Darrell S ^d   Gerami, Pedram ^e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b National Society for Cutaneous Medicine   (United States)

^c Castle Biosciences Incorporated   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

American Joint Committee on Cancer; cutaneous melanoma; gene expression profile; metastasis; prognosis; staging

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CUTANEOUS MELANOMA; DISTANT METASTASIS FREE SURVIVAL; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PRIORITY JOURNAL; SURVIVAL PREDICTION; TERTIARY CARE CENTER; ADOLESCENT; ADULT; AGED; CANCER STAGING; GENETICS; KAPLAN MEIER METHOD; MELANOMA; METASTASIS; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SECONDARY; SKIN TUMOR; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

TRANSCRIPTOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; HUMANS; KAPLAN-MEIER ESTIMATE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SKIN NEOPLASMS; SURVIVAL RATE; TRANSCRIPTOME; YOUNG ADULT;

EID: 85009727051     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.11.051     Document Type: Article

References (21)

1. 1 Balch, C.M., Gershenwald, J.E., Soong, S.J., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27 (2009), 6199–6206.
2. 2 Balch, C.M., Gershenwald, J.E., Soong, S.J., et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28 (2010), 2452–2459.
3. 3 Balch, C.M., Soong, S.J., Gershenwald, J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19 (2001), 3622–3634.
4. 4 Edge, S.B., Compton, C.C., The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17 (2010), 1471–1474.
5. 5 Morton, D.L., Thompson, J.F., Cochran, A.J., et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355 (2006), 1307–1317.
6. 6 Coit, D.G., Andtbacka, R., Anker, C.J., et al. Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 11 (2013), 395–407.
7. 7 Morton, D.L., Thompson, J.F., Cochran, A.J., et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370 (2014), 599–609.
8. 8 Nishino, M., Giobbie-Hurder, A., Ramaiya, N.H., Hodi, F.S., Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer, 2, 2014, 40.
9. 9 Del Vecchio, M., Ascierto, P.A., Mandala, M., et al. Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. Future Oncol 11 (2015), 1355–1362.
10. 10 Andtbacka, R.H., Kaufman, H.L., Collichio, F., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33 (2015), 2780–2788.
11. 11 Gerami, P., Cook, R.W., Russell, M.C., et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients with sentinel lymph node biopsy. J Am Acad Dermatol 72 (2015), 780–785.e3.
12. 12 Gerami, P., Cook, R.W., Wilkinson, J., et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res 21 (2015), 175–183.
13. 13 Soong, S.J., Ding, S., Coit, D., et al. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC melanoma database. Ann Surg Oncol 17 (2010), 2006–2014.
14. 14 Bartlett, E.K., Gimotty, P.A., Sinnamon, A.J., et al. Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy. Ann Surg Oncol 21 (2014), 643–649.
15. 15 Cooper, C., Wayne, J.D., Damstetter, E.M., et al. A 10-year, single-institution analysis of clinicopathologic features and sentinel lymph node biopsy in thin melanomas. J Am Acad Dermatol 69 (2013), 693–699.
16. 16 Han, D., Zager, J.S., Shyr, Y., et al. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol 31 (2013), 4387–4393.
17. 17 Hinz, T., Ahmadzadehfar, H., Wierzbicki, A., et al. Prognostic value of sentinel lymph node biopsy in 121 low-risk melanomas (tumor thickness <1.00 mm) on the basis of a long-term follow-up. Eur J Nucl Med Mol Imaging 39 (2012), 581–588.
18. 18 Mozzillo, N., Pennacchioli, E., Gandini, S., et al. Sentinel node biopsy in thin and thick melanoma. Ann Surg Oncol 20 (2013), 2780–2786.
19. 19 Wong, S.L., Brady, M.S., Busam, K.J., et al. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 13 (2006), 302–309.
20. 20 Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J., et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomized, double-blind, phase 3 trial. Lancet Oncol 16 (2015), 522–530.
21. 21 Berger, A.C., Davidson, R.S., Poitras, J.K., et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. Curr Med Res Opin 32 (2016), 1599–1604.